Work

Abstract LB-302: Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-lb-302

Authors: Alison M. Schram, Barry S. Taylor, Jaclyn F. Hechtman, Ryma Benayed, Lu Wang, Bethany Hanusch, Robert Young, Christian Grommes, Nora Ku, David M. Hyman, Thomas Kaley, Alexander Drilon

Institutions: Memorial Sloan Kettering Cancer Center, Loxo Oncology at Lilly (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2740860801

Cites:

Cited by: 8

Related to: 10